Table 3.
Degree and Percentile of Degree Distribution | ||||||
---|---|---|---|---|---|---|
Type of Sampling and Mean Degree | 10th Percentile c | 25th Percentile | Median | 75th Percentile | Maximum | P Value b |
Target statistics for empirical network | ||||||
5-SNP threshold | 0 | 0 | 1 | 7 | 62 | |
3-SNP threshold | 0 | 0 | 0 | 1 | 22 | |
Cases sampled preferentially by smear status (scenario 3)d | ||||||
50/50 smear−/+ (empirical network: 30/70 smear−/+) | ||||||
2 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–1) | 4 (4–5) | 0 (0–0) |
5 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–2) | 7 (7–8) | 0 (0–0) |
10 | 0 (0–0) | 0 (0–0) | 1 (1–1) | 3 (3–3) | 11 (10–12) | 0 (0–0) |
20 | 0 (0–0) | 1 (1–1) | 3 (2–3) | 6 (6–6) | 18 (17–19) | 0 (0–0) |
70/30 smear−/+ (empirical network: 30/70 smear−/+) | ||||||
2 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 4 (4–5) | 0 (0–0) |
5 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–1) | 7 (6–7) | 0 (0–0) |
10 | 0 (0–0) | 0 (0–0) | 1 (1–1) | 2 (2–3) | 11 (10–12) | 0 (0–0) |
20 | 0 (0–0) | 0 (0–1) | 2 (2–2) | 5 (5–5) | 19 (18–21) | 0 (0–0) |
Unmeasured factor (scenario 4) (40×, P = 0.10) | ||||||
2 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 7 (6–8) | 0 (0–0) |
5 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–1) | 14 (12–15) | 0 (0–0) |
8 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–1) | 30 (28–32) | 0 (0–0) |
10 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 1 (1–1) | 36 (34–38) | 0 (0–0) |
20 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 2 (2–3) | 62 (60–63) | 0 (0–0.002) |
Abbreviations: SNP, single nucleotide polymorphism; TB, tuberculosis; TRAX Study, Transmission Study of XDR TB; XDR, extensively drug-resistant.
a 1,000 networks were simulated from each model; each modeled network was sampled once.
b P values from a Kolmogorov-Smirnov test with a 2-sided alternative hypothesis, calculated using 1,000 bootstrap samples. P values shown as 0 were less than 2.2e-16.
c Median of the 10th percentile of the degree distribution from 1,000 modeled, sampled networks.
d Smear distribution among TRAX cases (in empirical network): 32% smear-negative, 68% smear-positive.